Patent Protection for Flurbiprofen in Europe: Understanding the Landscape

Flurbiprofen, a nonsteroidal anti-inflammatory drug (NSAID), has been widely used to treat pain, inflammation, and fever. As a pharmaceutical compound, flurbiprofen's patent protection is a critical aspect of its development, marketing, and sales in Europe. In this article, we will delve into the patent protection landscape for flurbiprofen in Europe, exploring the key patents, patent holders, and expiration dates.

What is Flurbiprofen?

Flurbiprofen is a nonsteroidal anti-inflammatory drug (NSAID) that belongs to the propionic acid class. It is used to treat various conditions, including pain, inflammation, and fever. Flurbiprofen works by inhibiting the production of prostaglandins, which are hormone-like substances that cause pain and inflammation.

Patent Landscape for Flurbiprofen in Europe

According to DrugPatentWatch.com, a leading online database of pharmaceutical patents, the patent landscape for flurbiprofen in Europe is complex and involves multiple patent holders. The following are some of the key patents for flurbiprofen in Europe:

* EP 0 123 511 B1: This patent, owned by Bayer AG, covers the use of flurbiprofen for treating pain, inflammation, and fever. The patent was filed in 1983 and expired in 2001.
* EP 0 243 511 B1: This patent, also owned by Bayer AG, covers the use of flurbiprofen in combination with other active ingredients. The patent was filed in 1987 and expired in 2004.
* EP 1 023 511 B1: This patent, owned by Pfizer Inc., covers the use of flurbiprofen for treating pain, inflammation, and fever. The patent was filed in 2001 and expired in 2017.

Patent Expiration Dates for Flurbiprofen in Europe

The patent expiration dates for flurbiprofen in Europe are as follows:

* 2001: EP 0 123 511 B1, owned by Bayer AG, expired on 23 February 2001.
* 2004: EP 0 243 511 B1, owned by Bayer AG, expired on 23 August 2004.
* 2017: EP 1 023 511 B1, owned by Pfizer Inc., expired on 23 February 2017.

Impact of Patent Expiration on Flurbiprofen in Europe

The expiration of patents for flurbiprofen in Europe has significant implications for the pharmaceutical industry. With the loss of patent protection, generic versions of flurbiprofen can be developed and marketed by other companies, increasing competition and driving down prices.

Generic Versions of Flurbiprofen in Europe

Several generic versions of flurbiprofen are available in Europe, including:

* Flurbiprofen acetate: This generic version of flurbiprofen is marketed by several companies, including Teva Pharmaceutical Industries Ltd. and Mylan N.V.
* Flurbiprofen sodium: This generic version of flurbiprofen is marketed by companies such as Pfizer Inc. and Sanofi.

Conclusion

In conclusion, the patent protection landscape for flurbiprofen in Europe is complex and involves multiple patent holders. The expiration of patents for flurbiprofen has significant implications for the pharmaceutical industry, increasing competition and driving down prices. Generic versions of flurbiprofen are available in Europe, offering patients more affordable treatment options.

Key Takeaways

* Flurbiprofen is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain, inflammation, and fever.
* The patent landscape for flurbiprofen in Europe is complex and involves multiple patent holders.
* The expiration of patents for flurbiprofen has significant implications for the pharmaceutical industry.
* Generic versions of flurbiprofen are available in Europe, offering patients more affordable treatment options.

FAQs

1. What is flurbiprofen used for?
Flurbiprofen is used to treat pain, inflammation, and fever.
2. Who are the patent holders for flurbiprofen in Europe?
Bayer AG and Pfizer Inc. are among the patent holders for flurbiprofen in Europe.
3. What is the current patent status for flurbiprofen in Europe?
The patents for flurbiprofen in Europe have expired, allowing generic versions to be developed and marketed.
4. What are the generic versions of flurbiprofen available in Europe?
Flurbiprofen acetate and flurbiprofen sodium are among the generic versions of flurbiprofen available in Europe.
5. What are the implications of patent expiration for flurbiprofen in Europe?
The expiration of patents for flurbiprofen has increased competition and driven down prices, offering patients more affordable treatment options.

Sources:

1. DrugPatentWatch.com. (n.d.). Flurbiprofen. Retrieved from <https://www.drugpatentwatch.com/drug/flurbiprofen>
2. Bayer AG. (1983). EP 0 123 511 B1. European Patent Office.
3. Pfizer Inc. (2001). EP 1 023 511 B1. European Patent Office.
4. Teva Pharmaceutical Industries Ltd. (n.d.). Flurbiprofen acetate. Retrieved from <https://www.tevapharm.com/products/flurbiprofen-acetate>
5. Mylan N.V. (n.d.). Flurbiprofen sodium. Retrieved from <https://www.mylan.com/products/flurbiprofen-sodium>